Business Wire

Lyndra Therapeutics Doses First Clinical Trial Participant in Study of Oral Biweekly Ivermectin (LYN-163) as a Tool in the Fight to Eradicate Malaria

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics, a clinical-stage biopharmaceutical company working to make daily pills a thing of the past, today announced it has dosed the first participant ...
MarketWatch

Lyndra Therapeutics Announces Strategic Clinical Research and Commercial Manufacturing Services Collaboration with Thermo Fisher Scientific for Long-Acting Oral Therapies

The MarketWatch News Department was not involved in the creation of this content. Lyndra Therapeutics Announces Strategic Clinical Research and Commercial Manufacturing Services Collaboration with ...
EurekAlert!

Lyndra scientists develop ultra long-acting oral drug delivery platform

Cambridge, MA - Lyndra, a healthcare company developing ultra long-acting oral drug delivery technologies, announced the publication of a scientific paper describing its novel technology in one of its ...
GEN

Lyndra Therapeutics Signs Manufacturing Agreement with Thermo for Long-Acting Oral Therapies

Lyndra Therapeutics, a clinical-stage biopharma firm, entered into a strategic collaboration with Thermo Fisher Scientific in which Thermo will provide global clinical research and commercial ...